Table 1.
Characteristics of All Included Studies.
| Study ID | Country | Study Design | Sample Case | Radiation | IC | TNM(AJCC) | Follow-up(months) | Outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Gender(M/F) | EBV-DNA≥4000 copies/ml | EBV-DNA<4000 copies/ml | ||||||||||
| IC+CCRT | CCRT | IC+CCRT | CCRT | ||||||||||
| Du et al. (24) | China | Retrospective | 881 | 674/207 | 284 | 152 | 186 | 259 | IMRT | platinum-basedregimen | III–IVB(7th) | 38.7 | PFS, DMFS |
| Peng et al. (25) | China | Retrospective | 290 | 217/73 | NA | NA | 145 | 145 | IMRT | PF, TP, TPF | III-IVB(7th) | NA | OS, DFS, DMFS, LRFS |
| Guo et al. (26) | China | Retrospective | 156 | 118/38 | 79 | 77 | NA | NA | IMRT | PF | III-IVB(7th) | 51.3 | OS, PFS, DMFS, LRFS |
| Jin et al. (27) | China | Retrospective | 639 | 482/157 | NA | NA | 296 | 343 | IMRT | PF | II-IVB(7th) | 58 | OS, PFS, DMFS, LRFS |
| Zhang et al. (28) | China | Retrospective | 1890 | 1364/526 | 945 | 945 | NA | NA | IMRT | PF, TP, TPF | III-IVA(8th) | NA | OS, DFS, DMFS, LRFS |
| Liu et al. (29) | China | Retrospective | 1312 | NA | 369 | 205 | 303 | 435 | IMRT | PF, TP, TPF | III-IVB(7th) | NA | OS, PFS, DMFS |
| Li et al. (30) | China | RCT | 121 | NA | 58 | 63 | NA | NA | IMRT | TPF | III-IVB(7th) | 71.5 | OS, FFS |
NA, Not applicable; EBV-DNA, Epstein-Barr virus deoxyribonucleic acid; IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy; IMRT, intensity modulated radiation therapy; PF, cisplatin and fluorouracil; TP, docetaxel and cisplatin; TPF, docetaxel, cisplatin and fluorouracil; OS, overall survival; PFS, progression free survival; DMFS, distance metastasis free survival; LRFS, local recurrence free survival; DFS, disease free survival; FFS, failure free survival; TNM (AJCC), American Joint Committee on Cancer Tumor-Node-Metastasis Staging for Nasopharyngeal Cancer (7th/8th edition).